Keap1-Nrf2 Pathway: a Key Mechanism in the Occurrence and Development of Cancer

Overview

Journal Front Oncol

Specialty Oncology

Date 2024 Apr 18

PMID 38634043

Authors

Feilong Chen

Mei Xiao

Shaofan Hu

Meng Wang

Affiliations

Soon will be listed here.

Abstract

The Keap1-Nrf2 signaling pathway is a major regulator of the cytoprotective response, participating in endogenous and exogenous stress caused by ROS (reactive oxygen species). Nrf2 is the core of this pathway. We summarized the literature on Keap1-Nrf2 signaling pathway and summarized the following three aspects: structure, function pathway, and cancer and clinical application status. This signaling pathway is similar to a double-edged sword: on the one hand, Nrf2 activity can protect cells from oxidative and electrophilic stress; on the other hand, increasing Nrf2 activity can enhance the survival and proliferation of cancer cells. Notably, oxidative stress is also considered a marker of cancer in humans. Keap1-Nrf2 signaling pathway, as a typical antioxidant stress pathway, is abnormal in a variety of human malignant tumor diseases (such as lung cancer, liver cancer, and thyroid cancer). In recent years, research on the Keap1-Nrf2 signaling pathway has become increasingly in-depth and detailed. Therefore, it is of great significance for cancer prevention and treatment to explore the molecular mechanism of the occurrence and development of this pathway.

Citing Articles

Antioxidant-Rich Functional Foods and Exercise: Unlocking Metabolic Health Through Nrf2 and Related Pathways.

Tkaczenko H, Kurhaluk N Int J Mol Sci. 2025; 26(3).

PMID: 39940866 PMC: 11817741. DOI: 10.3390/ijms26031098.

Exploring Chemoprevention in Colorectal Cancer for Patients with Inflammatory Bowel Disease: Mechanisms of Action and Clinical Aspects.

Fousekis F, Mpakogiannis K, Filis P, Skamnelos A, Christodoulou D, Mauri D Cancers (Basel). 2025; 17(2).

PMID: 39858011 PMC: 11764170. DOI: 10.3390/cancers17020229.

Effects of Lysophospholipids on the Antioxidant Capacity, Digestive Performance, and Intestinal Microbiota of .

Yan H, Wang Y, Liang H, Duan Y, Wang J, Zhou C Biology (Basel). 2025; 14(1).

PMID: 39857320 PMC: 11761955. DOI: 10.3390/biology14010090.

Luteolin induces oxidative stress and apoptosis via dysregulating the cytoprotective Nrf2-Keap1-Cul3 redox signaling in metastatic castration-resistant prostate cancer cells.

Eryilmaz I, Colakoglu Bergel C, Arioz B, Huriyet N, Cecener G, Egeli U Mol Biol Rep. 2024; 52(1):65.

PMID: 39699825 DOI: 10.1007/s11033-024-10178-4.

Sulforaphane attenuates phosgene-induced acute lung injury via the Nrf2-HO-1/NQO1 pathway.

Lu Q, Huang S, Zhao Y, Yu S, Shi M, Li J J Thorac Dis. 2024; 16(10):6604-6615.

PMID: 39552873 PMC: 11565325. DOI: 10.21037/jtd-24-819.

References

Wu S, Lu H, Bai Y . Nrf2 in cancers: A double-edged sword. Cancer Med. 2019; 8(5):2252-2267. PMC: 6536957. DOI: 10.1002/cam4.2101. View

Kansanen E, Kuosmanen S, Leinonen H, Levonen A . The Keap1-Nrf2 pathway: Mechanisms of activation and dysregulation in cancer. Redox Biol. 2013; 1:45-9. PMC: 3757665. DOI: 10.1016/j.redox.2012.10.001. View

Satoh T, McKercher S, Lipton S . Nrf2/ARE-mediated antioxidant actions of pro-electrophilic drugs. Free Radic Biol Med. 2013; 65:645-657. PMC: 3859717. DOI: 10.1016/j.freeradbiomed.2013.07.022. View

Egbujor M, Petrosino M, Zuhra K, Saso L . The Role of Organosulfur Compounds as Nrf2 Activators and Their Antioxidant Effects. Antioxidants (Basel). 2022; 11(7). PMC: 9311638. DOI: 10.3390/antiox11071255. View

Wufuer R, Fan Z, Liu K, Zhang Y . Differential Yet Integral Contributions of Nrf1 and Nrf2 in the Human HepG2 Cells on Antioxidant Cytoprotective Response against -Butylhydroquinone as a Pro-Oxidative Stressor. Antioxidants (Basel). 2021; 10(10). PMC: 8533631. DOI: 10.3390/antiox10101610. View

Zhang Y, Xiang Y . Molecular and cellular basis for the unique functioning of Nrf1, an indispensable transcription factor for maintaining cell homoeostasis and organ integrity. Biochem J. 2016; 473(8):961-1000. DOI: 10.1042/BJ20151182. View

Keleku-Lukwete N, Suzuki M, Yamamoto M . An Overview of the Advantages of KEAP1-NRF2 System Activation During Inflammatory Disease Treatment. Antioxid Redox Signal. 2017; 29(17):1746-1755. DOI: 10.1089/ars.2017.7358. View

Ma Q, He X . Molecular basis of electrophilic and oxidative defense: promises and perils of Nrf2. Pharmacol Rev. 2012; 64(4):1055-81. PMC: 4648289. DOI: 10.1124/pr.110.004333. View

Tate J, Bamford S, Jubb H, Sondka Z, Beare D, Bindal N . COSMIC: the Catalogue Of Somatic Mutations In Cancer. Nucleic Acids Res. 2018; 47(D1):D941-D947. PMC: 6323903. DOI: 10.1093/nar/gky1015. View

10.

Tao S, Liu P, Luo G, Rojo de la Vega M, Chen H, Wu T . p97 Negatively Regulates NRF2 by Extracting Ubiquitylated NRF2 from the KEAP1-CUL3 E3 Complex. Mol Cell Biol. 2017; 37(8). PMC: 5376629. DOI: 10.1128/MCB.00660-16. View

11.

Camina N, Penning T . Genetic and epigenetic regulation of the NRF2-KEAP1 pathway in human lung cancer. Br J Cancer. 2021; 126(9):1244-1252. PMC: 9042933. DOI: 10.1038/s41416-021-01642-0. View

12.

Yamamoto M, Kensler T, Motohashi H . The KEAP1-NRF2 System: a Thiol-Based Sensor-Effector Apparatus for Maintaining Redox Homeostasis. Physiol Rev. 2018; 98(3):1169-1203. PMC: 9762786. DOI: 10.1152/physrev.00023.2017. View

13.

Hirose W, Oshikiri H, Taguchi K, Yamamoto M . The KEAP1-NRF2 System and Esophageal Cancer. Cancers (Basel). 2022; 14(19). PMC: 9564177. DOI: 10.3390/cancers14194702. View

14.

Fabrizio F, Sparaneo A, Trombetta D, Muscarella L . Epigenetic versus Genetic Deregulation of the KEAP1/NRF2 Axis in Solid Tumors: Focus on Methylation and Noncoding RNAs. Oxid Med Cell Longev. 2018; 2018:2492063. PMC: 5872633. DOI: 10.1155/2018/2492063. View

15.

Slocum S, Kensler T . Nrf2: control of sensitivity to carcinogens. Arch Toxicol. 2011; 85(4):273-84. DOI: 10.1007/s00204-011-0675-4. View

16.

Fabrizio F, Costantini M, Copetti M, la Torre A, Sparaneo A, Fontana A . Keap1/Nrf2 pathway in kidney cancer: frequent methylation of KEAP1 gene promoter in clear renal cell carcinoma. Oncotarget. 2017; 8(7):11187-11198. PMC: 5355256. DOI: 10.18632/oncotarget.14492. View

17.

Fagerberg L, Hallstrom B, Oksvold P, Kampf C, Djureinovic D, Odeberg J . Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics. Mol Cell Proteomics. 2013; 13(2):397-406. PMC: 3916642. DOI: 10.1074/mcp.M113.035600. View

18.

Liu G, Eggler A, Dietz B, Mesecar A, Bolton J, Pezzuto J . Screening method for the discovery of potential cancer chemoprevention agents based on mass spectrometric detection of alkylated Keap1. Anal Chem. 2005; 77(19):6407-14. DOI: 10.1021/ac050892r. View

19.

Shi W, Ling L, Li C, Wu R, Zhang M, Shao F . LncRNA UCA1 promoted cisplatin resistance in lung adenocarcinoma with HO1 targets NRF2/HO1 pathway. J Cancer Res Clin Oncol. 2022; 149(3):1295-1311. DOI: 10.1007/s00432-022-04152-5. View

20.

Cunningham F, Achuthan P, Akanni W, Allen J, Amode M, Armean I . Ensembl 2019. Nucleic Acids Res. 2018; 47(D1):D745-D751. PMC: 6323964. DOI: 10.1093/nar/gky1113. View